It’s estimated that between 1 and 6 percent of the global population is suffering from moderate to serious OSAS. Obstructive sleep apnea syndrome includes a direct effect on standard of living and health, and can also result in serious cardiovascular disorders, like heart episodes and cerebrovascular mishaps . Related StoriesSleep apnea may increase gout pain riskCPAP therapy lowers depressive symptoms in people who have obstructive sleep apneaApplying a high restaurant model to health care communications: an interview with Brandi Robinson, SanofiAlthough this problem is widespread, around 80 percent of individuals concerned are not aware that they have problems with obstructive rest apnea.No unique safety concerns were identified in individuals undergoing major surgery. All individuals who received prophylactic rFIXFc, including those with a high regularity of bleeding before research entry, got marked reductions in the annualized bleeding rate, as compared with sufferers who received episodic treatment. Before study entry, 80 percent or even more of individuals treated prophylactically required shots at least 2 times per week, whereas during the scholarly study, prophylaxis was effective with shots administered every 1 to 2 2 weeks. These dosing intervals are than those observed in prior trials of recombinant aspect IX longer. The terminal half-existence of rFIXFc was 82.1 hours. The terminal half-life for recombinant element IX , which we calculated through pharmacokinetic sampling over the course of 96 hours, was substantially longer than that reported in some previous studies based on 48-hour sampling ,14,16,25,26,28 whereas it was more in line with the terminal half-life in studies that performed 72-hour sampling .13,27,29-31 When we analyzed the pharmacokinetics of recombinant factor IX on the basis of sampling for only 48 hours , the terminal half-life was 17.0 hours, which is consistent with the results of the studies using 48-hour sampling, thus confirming the method used in our analysis of recombinant factor IX.